HLB PANAGENE Co., LTD. (KOSDAQ:046210)

Market Cap	85.88B
Revenue (ttm)	13.33B
Net Income (ttm)	-3.10B
Shares Out	45.13M
EPS (ttm)	-74.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,261
Average Volume	52,083
Open	1,860.00
Previous Close	1,879.00
Day's Range	1,860.00 - 1,910.00
52-Week Range	1,665.00 - 3,860.00
Beta	0.13
RSI	36.62
Earnings Date	Aug 14, 2025

About HLB PANAGENE Co., LTD.

HLB PANAGENE Co., LTD. develops products in the field of molecular diagnostics in South Korea. Its products include liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company also offers products for cervical cancer, sexually transmitted, and extreme drug resistance diseases; and peptide nucleic acid products. The co...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1976
• Employees: 81
• Stock Exchange: KOSDAQ
• Ticker Symbol: 046210

Financial Performance

In 2024, HLB PANAGENE Co., LTD.'s revenue was 13.20 billion, an increase of 7.71% compared to the previous year's 12.25 billion. Losses were -1.94 billion, -59.63% less than in 2023.